Amylyx Pharmaceuticals Reports First Quarter 2026 Financial Results
Amylyx reported a Q1 net loss of $41.3 million, or $0.37 per share, with cash, cash equivalents, and short-term investments totaling $279.8 million as of March 31, 2026. The company expects its current cash position to fund operations into 2028, covering the potential commercialization of avexitide, while R&D expenses increased to $27.6 million primarily due to clinical trial activity.
Key figures
- Guidance
- Q3 2026 topline data readout for Phase 3 LUCIDITY trial; commercial launch of avexitide anticipated in 2027
- Net loss
- 41284000
- Cash runway
- into 2028
- Rd expenses
- 27600000
- Sga expenses
- 16169000
- Cash position
- 279768000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.